ONT-380 has stage IV HER2+ breast cancer patient ‘worrying about normal stuff again’

Related posts:

1. Targeted drug can ‘diminish the suffering’ of myelofibrosis Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a researcher who co-led PERSIST-1, the worldwide phase 3 clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent. ...
2. Combining targeted drug with chemotherapy offers longer life to b-cell cancer patients Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia or small lymphocytic lymphoma, an interim analysis has closed the international HELIOS phase III clinical trial. ...
3. Phase 2 trial identifies genetic dysfunction that makes many types of cancer vulnerable to an immunotherapy A team of researchers has identified a genetic malfunction that predicts the effectiveness of response to a groundbreaking immunotherapy. The results of their Phase 2 clinical trial reveal that, regardless of its tissue of origin, tumors whose cells are deficient in repairing mismatched DNA sequences--and so preventing mutations--are far more susceptible to the checkpoint inhibitor pembrolizumab than those that retain this ability. ...
4. Blood pressure medications can lead to increased risk of stroke The importance of preventing hypertension is reinforced by a study showing anti-hypertension medicines can increase stroke risk by 248 percent, according to new research. ...
5. Dying cells can protect their stem cells from destruction An SOS signal from dying daughter cells allows their mother stem cells to protect themselves from radiation and chemotherapy damageCells dying as the result of radiation exposure or chemotherapy... ...